Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

XNCRBullishIndustry Newsnews

High materiality7/10

Xencor Advances XmAb819 with ESMO Data and 2027 Phase 3 Plan

Jul 17, 2026, 9:13 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive near-term catalyst from ESMO presentation and 2027 Phase 3 timing; risk remains due to early-phase data and competition, but data-driven momentum often drives small-cap biotechs.

AI summary

What happened, with direct paths to the underlying reporting

Xencor announced that XmAb819 Phase 1 results in ENPP3+ ccRCC were accepted for an ESMO 2026 proffered paper, with expansion cohorts guiding the Phase 3 dose. A pivotal monotherapy trial for advanced ccRCC is planned to start in 2027, while IV and subcutaneous dosing expansion and IO-combination sub-studies open in 2026, potentially expanding XmAb819’s addressable tumors and setting up a late-2020s catalyst.

XmAb819 Phase 1 ccRCC data accepted for ESMO 2026; expansion cohorts guide Phase 3 dose.
Pivotal XmAb819 monotherapy in advanced ccRCC planned to begin in 2027.
Expansion cohorts evaluate IV doses; subcutaneous dosing is ongoing.
IO doublet after nivolumab+ipilimumab referenced; IO-context matters for XmAb819.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.